GlassScriptPhysician profile
Amy L Tobin
NPI 1093743007
$36,529.43
in general payments reported to CMS, 2019-2025
69 companies · $5,456 in 2025
The $5,456 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,566 · 2020: $2,712 · 2021: $4,357 · 2022: $5,344 · 2023: $4,983 · 2024: $6,112 · 2025: $5,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $1,050 · Travel and Lodging: $386 · Education: $83.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,031.68 |
| Consulting Fee | $1,050.00 |
| Travel and Lodging | $385.93 |
| Education | $83.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,422.31 | 2019-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $3,626.65 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $2,626.13 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $2,562.37 | 2019-2025 | Freestyle Libre Pro, Freestyle Libre 3 |
| Cequr Corporation | $2,443.07 | 2021-2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $2,254.61 | 2019-2020 | |
| Lilly USA, LLC | $2,120.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,801.04 | 2019-2023 | Farxiga |
| Dexcom, INC. | $1,439.09 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Mannkind Corporation | $1,145.52 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $1,052.58 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $833.18 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $823.41 | 2021-2025 | |
| Corcept Therapeutics | $739.77 | 2019-2025 | Korlym |
| Abbvie INC. | $608.59 | 2019-2025 | Synthroid, Ubrelvy |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $545.29 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ascendis Pharma Endocrinology INC | $431.65 | 2023-2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.14 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $371.12 | 2021-2025 | Tymlos |
| Becton, Dickinson and Company | $335.49 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $314.66 | 2019-2025 | Unithroid |
| Amarin Pharma, INC. | $307.32 | 2019-2022 | |
| Horizon Therapeutics Plc | $275.70 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $254.66 | 2019-2020 | |
| Madrigal Pharmaceuticals | $252.42 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $244.65 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Lifescan, INC. | $242.61 | 2019-2023 | |
| Kyowa Kirin, INC. | $232.99 | 2025 | |
| Senseonics, Incorporated | $230.00 | 2019-2020 | |
| Vistapharm, INC. | $224.74 | 2021 | |
| Sequel Med Tech, LLC | $217.84 | 2025 | Twiist |
| Insulet Corporation | $209.18 | 2019-2024 | Omnipod |
| Nevro Corp. | $203.01 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $186.91 | 2019-2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $177.58 | 2019-2022 | |
| Esperion Therapeutics, INC. | $161.08 | 2021-2024 | Nexletol |
| Valeritas, INC. | $152.88 | 2019 | |
| Recordati_rare_diseases_inc. | $150.44 | 2020-2025 | Isturisa, Signifor Lar |
| Alvogen INC | $146.75 | 2022-2025 | Teriparatide |
| Ascensia Diabetes Care US INC. | $145.53 | 2024-2025 | |
| Clarus Therapeutics INC. | $137.44 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $120.62 | 2021-2023 | Somatuline Depot |
| Alexion Pharmaceuticals, INC. | $111.36 | 2019-2024 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.05 | 2019-2020 | |
| Amphastar Pharmaceuticals, INC. | $90.46 | 2024-2025 | |
| Shire North American Group INC | $88.14 | 2019 | |
| Averitas Pharma INC. | $85.25 | 2023-2025 | Qutenza |
| Pfizer INC. | $84.08 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $76.36 | 2024-2025 | Crenessity |
| Amryt Pharma Holdings LTD | $75.06 | 2022-2023 | Mycapssa |
| Embecta Corp. | $71.96 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ibsa Pharma INC. | $65.52 | 2019-2024 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $62.24 | 2021 | |
| Vivus LLC | $56.98 | 2020-2021 | |
| Chiesi USA, INC. | $51.14 | 2024-2025 | Mycapssa |
| Medline Industries LP | $45.28 | 2023 | |
| Beta Bionics, INC. | $39.33 | 2023-2024 | Ilet Bionic Pancreas |
| Zealand Pharma US, INC. | $39.11 | 2021 | |
| Tolmar, INC. | $31.86 | 2024-2025 | Jatenzo |
| Grt US Holding, INC. | $27.73 | 2022 | |
| Eisai INC. | $27.48 | 2019 | |
| Bigfoot Biomedical INC | $22.59 | 2022 | |
| Verity Pharmaceuticals INC. | $19.10 | 2025 | Tlando |
| Eusa Pharma (US) LLC | $18.33 | 2022 | |
| Companion Medical, INC. | $17.18 | 2020 | |
| Gilead Sciences, INC. | $15.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2021 | |
| Alfasigma USA, INC. | $13.21 | 2021 | |
| Theracosbio, LLC | $10.32 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.